Fibronectin Monoclonal Antibody (A17), Invitrogen™

Description

• CSI 005-17-02 is highly specific for fibronectin
• There is no evidence for cross-reactivity with other connective tissue proteins (vitronectin, elastin, collagen, laminin)
• CSI 005-17-02 cross-reacts with human and chicken fibronectin
• Other species have not been tested
• CSI 005-17-02 has been successfully used in Western blottin, ELISA, Immunohistochemistry and Immunoprecipitation procedures
• The antibody inhibits integrin-mediated cell adhesion to the cell binding domain of fibronectin
• It can be used to probe fibronectin conformation
• Strong reaction is seen in ELISA with thrombospondin directly coated onto the microtiter well
• The specificity of the CSI 005-17-02 epitope is located in the 120 kDa cell binding fragment
• NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL Fibronectin is a disulfide-bonded dimer with a molecular weight range of 230-250 kDa
• In the extracellular matrix of several connective tissues and vessels, fibronectin is present as an insoluble protein that is extensively cross-linked by interchain disulfide bonds forming high molecular mass polymers
• Fibronectin is most abundant during embryonic development and tissue remodeling
• Fibronectin is also present at high concentrations as a soluble plasma protein
• Fibronectin is organized as a linear series of repeating modules which form domains for interaction with fibronectin itself, other matrix components (e.g
• collagen and heparin) and receptors on cells (e.g
• integrins)
• Fibronectin is present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix
• Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis
• Fibronectin has been implicated in carcinoma development in lung cancer
• Further, Fibronectin expression is increased especially in non-small cell lung carcinoma
• The adhesion of lung carcinoma cells to Fibronectin enhances tumorgenecity and confers resistance to apoptosis induced by standard chemotherapeutic agents
• The gene encoding Fibronectin has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants
• However, the full-length nature of some Fibronectin variants has not been determined.